Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
A young TB patient in a hospital in South Africa
Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
21
Innovation

3 Ways Johnson & Johnson Is Innovating to Help Fight Tuberculosis

Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
21
It's one of the world's deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. As 2020 comes to a close, we're taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.
Today's Top Reads Close

1.4 million. That's how many people tuberculosis (TB) killed in 2019, despite it being a preventable and treatable disease.

For years, one of the biggest impediments to global efforts to tackle TB has been growing resistance to the most commonly used medicines to treat the disease—in 2019 alone, there were nearly 400,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most commonly-used TB medications currently available.

There's also the hurdle of diagnosis: While detection numbers had been on the rise prior to the COVID-19 pandemic, there are still approximately 3 million people living with TB who don't know they have the disease. And every individual who remains untreated can infect up to 15 additional people over the course of a year, further fueling the TB pandemic.

COVID-19 is also posing new challenges. Not only do people with TB fear that they may be uniquely vulnerable to severe complications from COVID-19 if infected, but the pandemic has also disrupted already stretched systems of delivering TB care.

“COVID-19 is threatening hard-won gains in the fight against TB,” says Ana-Maria Ionescu, TB Access Strategy & Impact Leader, Global Public Health, Johnson & Johnson. “At Johnson & Johnson, we are committed to doing our part, in collaboration with governments and partners, to ensure that patients continue to receive the care they need during these unprecedented times.”

For example, in response to COVID-19, Johnson & Johnson launched the DR-TB Lifeline QuickFire Challenge, which is providing support to five organizations working to ensure continuity of care for drug-resistant TB (DR-TB) patients in India, the Philippines, South Africa and Ukraine.

Before the pandemic, Johnson & Johnson also launched a historic 10-year initiative in 2018 aimed at helping improve disease detection; broaden access to its novel medicine for MDR-TB; and accelerate research to develop more next-generation medicines.

It's a critical project—and the company is well on its way to delivering on some of the key commitments.

As we get ready to wrap up this unprecedented year, we’re highlighting some of the strides Johnson & Johnson made through the initiative to help bring us closer to a TB-free world.


Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
21
expand

Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
21
Read about how the company is working to improve detection, broaden access to treatment, and accelerate research and development for the disease over the next decade.

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue